FundedIQ
Biotechnology

Royalty Pharma: Funding, Investors & Team (Oct 2026)

Royalty Pharma has built a successful business in the biopharmaceutical industry by acquiring revenue-generating intellectual property, primarily royalty interests in biopharmaceutical products that are already on the market or in late-stage development. Rather than developing or selling products themselves, Royalty Pharma provides cash to IP owners and takes on the risks and rewards of ownership. Since 1996, the company has partnered with research institutions, inventors, and biotech and pharma companies, and currently owns interests in 44 approved products and seven in clinical trials or under review by the FDA and EMA.

royaltypharma.com LinkedIn New York, United States 51-100 employees
Total raised
$1.5B
Rounds
1
Latest
Undisclosed round
Jun 2024

Royalty Pharma has raised $1.5B across 1 funding round on record, the most recent an undisclosed round of $1.5B announced in Jun 2024.

That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Royalty Pharma Company Profile and Key Stats

Total funding raised
$1.5B
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$1.5B in Jun 2024
Employees
51-100
reported band
Headquarters
New York, United States

Latest funding round on record: Jun 2024.

Royalty Pharma Funding Rounds

Date
Round
Amount
Undisclosed round
$1.5B

Royalty Pharma Founders and Leadership Team

Name
Role
Contact
Pablo Legoretta
Founder
Locked

Contact details for the Royalty Pharma team: 1 of 1 has an email address on file.

Start 14-day free trial →

Royalty Pharma Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,185
$8.4M
30,319
$7.7M

Royalty Pharma's latest round of $1.5B is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Royalty Pharma in Biotechnology and New York

Companies Similar to Royalty Pharma

Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…

Series B $50.0M

Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…

Series A $37.0M
Series B $150M

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…

Undisclosed round $94.0M

Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…

Series B $9.5M

Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…

Series B $33.0M

Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…

Undisclosed round —

Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.

Series A $15.0M

Serán is a contract development and manufacturing organization providing a comprehensive suite of…

Private Equity —

Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…

Series D $250M

Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…

Series E $311M

Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…

Undisclosed round $8.5M

Royalty Pharma Funding FAQs

What does Royalty Pharma do?

Royalty Pharma has built a successful business in the biopharmaceutical industry by acquiring revenue-generating intellectual property, primarily royalty interests in biopharmaceutical products that are already on the market or in late-stage development. Rather than developing or selling products themselves, Royalty Pharma provides cash to IP owners and takes on the risks and rewards of ownership. Since 1996, the company has partnered with research institutions, inventors, and biotech and pharma companies, and currently owns interests in 44 approved products and seven in clinical trials or under review by the FDA and EMA.

How much funding has Royalty Pharma raised?

Royalty Pharma has raised $1.5B across 1 round on record. The most recent is an undisclosed round of $1.5B announced in Jun 2024.

When did Royalty Pharma last raise funding?

Royalty Pharma's most recent funding round on record is an undisclosed round of $1.5B, announced in Jun 2024.

Who founded Royalty Pharma?

FundedIQ lists Pablo Legoretta (Founder) at Royalty Pharma.

Where is Royalty Pharma headquartered?

Royalty Pharma is based in New York, United States.

How many employees does Royalty Pharma have?

Royalty Pharma is in the 51-100 employee band.

How does Royalty Pharma's funding compare to other Biotechnology startups?

Royalty Pharma's latest round of $1.5B is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.

About FundedIQ's Royalty Pharma Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Royalty Pharma is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.

Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.